<DOC>
	<DOCNO>NCT01296412</DOCNO>
	<brief_summary>This study do compare effectiveness safety two treatment paradigm ( oral sitagliptin without glimepiride versus liraglutide without increased dosing ) treatment participant Type 2 Diabetes adequately control metformin alone . The primary hypothesis postulate mean change baseline hemoglobin A1c ( A1C ) participant treat sitagliptin-based treatment non-inferior participant treat liraglutide-based treatment .</brief_summary>
	<brief_title>Comparison Two Treatment Regimens ( Sitagliptin Versus Liraglutide ) Participants Who Failed Achieve Good Glucose Control Metformin Alone ( MK-0431-403 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Inclusion criterion Type 2 diabetes mellitus . On stable dose metformin monotherapy dose least 1500 mg per day least 12 week hemoglobin A1C ≥7.0 % ≤11.0 % . Capable use liraglutide pen device . Exclusion criterion History Type 1 Diabetes mellitus . Use oral antihyperglycemic agent ( AHA ) besides metformin , within prior 12 week screen . Cardiovascular disorder within past 3 month include acute coronary syndrome new worsen symptom coronary heart disease , coronary artery intervention , stroke , transient ischemic neurological disorder . Impaired liver function . Impaired kidney function . History malignancy clinically important hematological disorder require diseasespecific treatment ( chemotherapy , radiation therapy , surgery ) , opinion investigator , likely recur duration study . History leukemia , lymphoma , aplastic anemia , myeloproliferative myelodysplastic disease , thrombocytopenia , malignant melanoma , regardless time since treatment . Pregnancy breastfeeding , intention become pregnant donate egg within project duration study . Participation another study investigational drug device within 12 week prior screen . History hypersensitivity contraindication sitagliptin , liraglutide , glimepiride , metformin base upon label country investigational site . Participation weight loss program yet maintenance phase , start weight loss medication ( orlistat phentermine ) within prior 8 week . Surgery within prior 4 week major surgery plan study . Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia syndrome type 2 ( MEN 2 ) . User recreational illicit drug recent history ( within last year ) drug abuse increase alcohol consumption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>